General Information |
| Summary |
This study will evaluate the safety of an investigational cell transplantation therapy, ISC-hpNSC, in patients with Parkinson's disease. All patients will receive the therapy, which consists of human neural stem cells. Three dose levels will be examined in the study. |
| Description |
ISC-hpNSC is a cellular therapeutic consisting of human parthenogenetic neural stem cells (hpNSC). ISC-hpNSC will be injected intracerebrally to the striatum and substantia nigra of patients with Parkinson's disease (PD).
The study will enroll 4 patients for cell injection at each of three different doses. A total of 12 patients with moderate to severe PD will be treated. Each patient receives a single dose. The main objective of the study is to evaluate the safety of the cell transplantation. |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2016-07-01 |
| End date (estimated) |
2020-06-30 |
| Clinical feature |
| Label |
Parkinson's disease |
| Link |
http://purl.obolibrary.org/obo/DOID_14330 |
| Description |
A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
| Publications |
|
Administrative Information |
| NCT number |
NCT02452723 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT02452723 |
| Other study identifiers |
|
| Source weblink |
https://www.clinicaltrials.gov/ct2/show/NCT02452723 |
| Study sites |
|
| Sponsors |
Cyto Therapeutics Pty Limited |
Cells |
| Which differentiated cell type is used |
| Label |
neural stem cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000047 |
| Description |
An undifferentiated neural cell that originates from the neuroectoderm and has the capacity both to perpetually self-renew without differentiating and to generate multiple central nervous system neuronal and glial cell types. |
|
Recruitment |
| Recruitment Status |
Active, not recruiting |
| Estimated number of participants |
12 |
| Contact institutions/departments |
|